WD-1603 clinical trials
Also written WD-1603.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses WD-1603 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Hong Kong WD Pharmaceutical Co., Limited (3) · Shanghai WD Pharmaceutical Co., Ltd. (2)
Studies
Open first, then newest update. How each study uses WD-1603 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's DiseaseCompletedPhase 2Shanghai WD Pharmaceutical Co., Ltd.NCT05036473Written as WD-1603 Carbidopa-Levodopa Extended-Release TabletsHow we know
- Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed ConditionsCompletedPhase 1Shanghai WD Pharmaceutical Co., Ltd.NCT05128175Written as WD-1603 Carbidopa-Levodopa Extended-Release TabletsHow we know
- PK Study of WD-1603 in Healthy SubjectsStatus unknownPhase 1Hong Kong WD Pharmaceutical Co., LimitedNCT04591535Written as WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETSHow we know
- A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting ConditionsStatus unknownPhase 1Hong Kong WD Pharmaceutical Co., LimitedNCT04553978Written as WD-1603How we know
- WD-1603 PK Study Under Fasting and Fed Conditions in Healthy SubjectsStatus unknownPhase 1Hong Kong WD Pharmaceutical Co., LimitedNCT04513340Written as WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETSHow we know